Healthy Returns
March 29, 2023

Healthy Returns

Moonshots to Miracles
Medical innovation brings progress, and progress saves lives

CNBC Healthy Returns convenes a world-class virtual gathering of CEOs, scientists, investors and innovators in the health care space to reflect on the progress made today to reinvent the future of medicine, including the newest drug breakthroughs and device innovations. Plus, an exclusive rundown of the best investment opportunities in biopharma, health-tech and managed care.

WHO SHOULD ATTEND: Health care investors, VCs, C-Suite executives from the biotech, pharma, health care and life sciences industries, health care IT BDMs.


Dr. Nworah Ayogu

Dr. Nworah Ayogu is Chief Medical Officer and General Manager of Amazon Clinic. Prior to joining Amazon, Dr. Ayogu was the founding Medical Director for CityBlock Health. He has worked with governments, payers, and health systems to improve access and quality of care, and has published research in the multiple journals including the New England Journal of Medicine. In addition, he serves as a member of the White House Health Equity round table, and has held faculty appointments at Harvard and NYU. Dr. Ayogu obtained his MD from Harvard Medical School and his MBA from Harvard Business School. He trained in Internal Medicine at Columbia University and is a board-certified internist.

Jim Breyer

Jim is the Founder and CEO of Breyer Capital, a global venture capital firm based in Menlo Park, CA. Jim has been an investor in over 40 consumer internet/technology companies that have completed successful public offerings or mergers, including Facebook, Etsy, Legendary, Datalogix and Marvel Entertainment. As a lead investor and/or board member, Jim has assisted teams at over a dozen companies complete IPOs. Several of his investments have returned to investors over 100 times their cost, and over a dozen more have returned over 25 times cost.

Over the past several years, Jim has developed a deep personal and investment interest in long-term oriented entrepreneurs and teams working in artificial intelligence (AI) and human assisted intelligence (HAI) and he has made numerous investments in this space.

Jim also has a long track record of investing in China and partnering with Chinese entrepreneurs, including through Breyer Capital’s major limited partnership with IDG Capital, a premier technology venture capital firm based in Beijing. Jim has been actively involved with IDG China for well over a decade and currently plays the leading outside strategic advisory role for the firm. IDG’s investments in China include Xiaomi, Baidu and Tencent, among others.

Jim currently serves on the board of directors of Blackstone and 21st Century Fox, where he is Chairman of the Compensation Committee and a member of the Nominating Committee. Jim served on Facebook’s board from 2005 to 2013 after leading the company’s Series A funding round. He served on Etsy’s board from 2008 to 2016 and was the company’s largest outside shareholder at the time of its IPO in 2015. Notably, Etsy is one of the first B Corporations to successfully go public and continue to grow significantly post-offering.

Jim was the lead investor for Legendary Entertainment’s first funding round and served as a board member until its acquisition by Dalian Wanda in March 2016. He was also an investor and board member of Marvel Entertainment through its acquisition by Disney in 2009. Jim’s other board memberships include Wal-Mart, where he served for
over a decade and was the lead independent director until his retirement in 2013, and Dell Inc., where he was a director through the company’s $24 billion take-private in 2013.

Jim is passionate about philanthropy and applying venture philanthropy and innovation models to areas such as education, the arts, and environmental sustainability. Jim is a Fellow of Harvard Corporation, Harvard’s senior governing board; a member of Harvard Business School’s Board of Dean’s Advisors since 2001; a member of Harvard University’s Global Advisory Council since inception; a founding member of the Dean’s Advisory Board at Stanford’s School of Engineering; Chairman of the Stanford Engineering Venture Fund; and Chairman of the Advisory Board at the Tsinghua University School of Economics and Management. He is passionate about the Breyer Center at Stanford-in-Florence and is a former Trustee of Menlo School (a grade 6-12 school in Atherton, CA).

In addition, Jim is a long-time Trustee of SFMOMA, The Metropolitan Museum of Art in New York and the American Film Institute (AFI) in Los Angeles. He is actively involved in The Environmental Defense Fund and Stanford’s Center for Philanthropy and Civil Society (PACS).

Jim began his career at Accel, where he was a partner for nearly three decades and served as Managing Partner.

He also co-founded AKKR, a joint venture between Accel and KKR in 2000. Jim graduated from Stanford University with a BS degree, and from Harvard University with an MBA, where he was named a Baker Scholar.

Lars Fruergaard Jørgensen

Lars Jørgensen joined Novo Nordisk in 1991 as an economist in Health Care, Economy & Planning and has over the years completed overseas postings in the Netherlands, the US and Japan. In 2004 he was appointed senior vice president for IT & Corporate Development. In January 2013 he was appointed executive vice president and chief information officer assuming responsibility for IT, Quality & Corporate Development. In November 2014 he took over the responsibilities for Corporate People & Organisation and Business Assurance and became chief of staff. Mr Jørgensen was appointed president and chief executive officer in January 2017.

Mr Jørgensen serves as First Vice-President at the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Emma Walmsley

Emma has been GSK CEO and Board Director since April 2017. Emma has been a member of the GSK Leadership Team since 2011, as the President and then CEO of GSK Consumer Healthcare. She chaired the Consumer Joint Venture with Pfizer until its demerger as Haleon in 2022.

Prior to joining GSK in 2010, Emma worked with L’Oreal for 17 years in global and local marketing and general management roles in Paris, London, New York and Shanghai.

Emma joined the Microsoft board as an independent director in 2019. She is a member of the Stanford Medicine Board of Fellows and a member of The Business Council Executive Committee in the US. She was previously a Non-Executive Director of Diageo.

Emma was appointed Dame Commander of the British Empire for services to the pharmaceutical industry and business in 2020.

Emma holds an MA in Classics and Modern Languages from Oxford University.

Stephen Squinto

Stephen Squinto, Ph.D. is chief investment officer & managing partner at J.P. Morgan Life Sciences Private Capital. Previously an executive partner with OrbiMed, he brings more than 30 years of experience in the biotechnology company building and investing space. He was a co-founder of Alexion Pharmaceuticals, Inc. and served as its executive VP and chief global operations officer. Prior to 2013, he was Alexion’s global head of R&D. While at Alexion, he was responsible for the discovery, development and launch of several successful biotechnology products. From 1988 to 1992, he held various positions at Regeneron Pharmaceuticals, Inc. Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools. Stephen is a recipient of numerous honors and awards from academic and professional organizations for his scientific work. He received his B.A. in chemistry and Ph.D. in biochemistry and biophysics from Loyola University of Chicago.

Dr. Sanjiv Patel

Sanjiv Patel brings to Relay Therapeutics more than 20 years of life sciences industry experience. Prior to Relay Therapeutics, Sanjiv was at Allergan for more than a decade, and played a key part in Allergan’s sustained growth and value creation over that period. Sanjiv held roles of increased responsibility, including leading global strategic marketing for all franchises and general management of Allergan’s fastest growth geographic region, the emerging markets. Sanjiv was most recently part of Allergan’s executive team as chief strategy officer, where he was at the center of some of the industry’s largest transactions. His work with the senior leadership team of Allergan defined its long-term objectives and strategy, including divestment and integration planning activities. Prior to Allergan, Sanjiv was a management consultant at Boston Consulting Group in London and he started his career as a surgeon in the U.K.’s National Health Service. Sanjiv holds an MBA from INSEAD, MBBS from the University of London and a M.A. in neurosciences from Cambridge University

Dr. Vineeta Agarwala

Vineeta Agarwala, MD, PhD, is a General Partner at Andreessen Horowitz where she leads investments for the firm’s bio + health fund across therapeutics, life sciences tools/diagnostics, and digital health, with a focus on companies leveraging unique datasets to improve drug development and patient care delivery.

Prior to joining a16z, Vineeta held many different roles in the healthcare space: as a physician taking care of patients; as an operator at healthtech startups; and as a venture investor on the Google Ventures life sciences team. She was an early data scientist at Kyruus; a management consultant for biotech, pharmaceutical, and medical device clients at McKinsey & Co; and a Director of Product Management at Flatiron Health, where she led the company’s partnership with Foundation Medicine to integrate real-world clinical and genomic data into national-scale data products to accelerate research and development in oncology. She has collaborated with academic researchers at Cold Spring Harbor Laboratory, Lawrence Livermore National Laboratory, and the Broad Institute, where she did graduate work in computational biology and human genetics.

Vineeta holds a B.S. in biophysics from Stanford University, and MD and PhD degrees from Harvard Medical School / MIT. She completed her clinical residency at Stanford, and is board certified in internal medicine. Vineeta continues to see patients at Stanford as an adjunct clinical professor in the Division of Primary Care and Population Health.

Vineeta serves on a number of portfolio company boards, including BigHat Biosciences, GC Therapeutics, Memora Health, Orbital Therapeutics, Pearl Health, Thyme Care, and Waymark.

Dr. Peter WT Pisters

Peter WT Pisters, M.D., M.H.C.M., has served as president of The University of Texas MD Anderson Cancer Center in Houston, Texas since December 2017. A renowned cancer surgeon, researcher, professor and administrator, Dr. Pisters established his career at MD Anderson, serving over 20 years in faculty and senior leadership positions. He left MD Anderson to serve as president and CEO of the University Health Network in Toronto, Canada’s largest research hospital, before returning to MD Anderson. Dr. Pisters earned his medical degree at Schulich School of Medicine and Dentistry at the University of Western Ontario in Canada before completing his postgraduate work at Memorial Sloan Kettering Cancer Center in New York. In 2014, he received a master’s degree in health care administration at the Harvard T.H. Chan School of Public Health in Boston.

Dr. Anand Shah

Anand Shah, M.D. is an Operating Advisor at private equity firm Clayton, Dubilier & Rice. Dr. Shah develops and identifies potential investment opportunities in the healthcare industry, with a focus on health care services, pharmaceutical services, and medical technology. He also serves as an advisor to the firm’s portfolio companies.

A nationally recognized physician leader and health policy expert, Dr. Shah has extensive healthcare experience in the senior-most levels of the U.S. government, private sector, and as a physician. He was previously the Deputy Commissioner for Medical and Scientific Affairs at the U.S. Food and Drug Administration (FDA). Dr. Shah led consensus policy development for fit-for-purpose programs including Advanced Manufacturing, the Coronavirus Treatment Acceleration Program, Covid vaccine development, digital health, consumer protection, and decentralized clinical trials. During the Covid pandemic, he led FDA’s policy development for preparedness and recovery efforts. Dr. Shah represented FDA with top-level policy makers of the White House and Cabinet, Governors and local governments, and regularly led briefings with Congressional leadership.

He previously served in two senior leadership roles at the Centers for Medicare & Medicaid Services (CMS). As Senior Medical Advisor, he was the primary counselor for agency-wide policy related to medical and scientific innovation. Dr. Shah established consensus on several critical policy initiatives including aligning payment and prevention to increase Medicare beneficiaries’ access to novel antimicrobials, expanding patients’ access to cell and gene therapies, and streamlining Medicare access to breakthrough technologies. As the Chief Medical Officer of the Center for Medicare & Medicaid Innovation (CMMI), Dr. Shah led the clinical design of novel value-based payment and service delivery models including those for primary and specialty care.

Dr. Shah specializes in the early detection, surveillance, and treatment of prostate cancer, and previously developed and led a survivorship clinic for patients on cancer clinical trials at the National Institutes of Health. His scientific track record includes publications in the New England Journal of Medicine, JAMA, Health Affairs, Cancer, and Nature Reviews Drug Discovery. Dr. Shah is an Adjunct Senior Fellow at the Leonard Davis Institute of Health Economics at the University of Pennsylvania.

Dr. Shah was chief resident during his radiation oncology residency at Columbia University. He concurrently earned his M.D. from the University of Pennsylvania and an M.P.H. in health care management and policy from the Harvard School of Public Health. Dr. Shah graduated with honors from Duke University with a degree in economics. He also served as a Canada-U.S. Fulbright Scholar.

Karin Conde-Knape

Karin Conde-Knape is the Senior Vice President for Global Drug Discovery/GDD within Novo Nordisk. Driving the early pipeline and innovation within the areas of Diabetes, Obesity, Cardiovascular, Renal, Rare endocrine and metabolic diseases. Experienced executive within the pharmaceutical industry for the last 20 years with different areas of responsibility, including project leadership, line management, strategic planning and execution as well as business development.

Karin spent 11 years at Hoffman-La Roche in the Cardiovascular and Metabolism Discovery and early development areas, responsible for pharmacology teams as well as discovery and biomarker teams. Before joining Novo Nordisk she spent 4 years at Johnson and Johnson, responsible for external innovation in Europe and Asia Pacific in the area of Cardiovascular and Metabolism. During these years she lead cross functional teams in the evaluation for external opportunities and creating the business cases to support deal making for different external opportunities.

Dominic Chu

Dominic Chu is a senior markets correspondent for CNBC, located at the network’s Global Headquarters in Englewood Cliffs, N.J. He appears during CNBC’s Business Day programming and contributes to

Previously, Chu was a New York-based markets correspondent for Bloomberg Television, where he covered the stock, bond, currency and commodities markets. During that time, he interviewed some of the world’s top money managers and business executives, and he also was part of the team that covered Hurricane Sandy and the Boston Marathon bombings. In addition, Chu handled sports business reporting for the network.

Chu brings extensive knowledge of the financial markets, having worked in sales and trading for UBS Investment Bank, mutual fund management for Hennessy Advisors and investment management for Seascape Capital.

He has spoken at numerous industry conferences and was a regular contributor to radio and television outlets across the country.

Chu holds a Bachelor of Science degree in hotel administration from Cornell University.

Jim Cramer

Jim Cramer believes there is always a bull market somewhere, and he wants to help you find it. He is host of CNBC's "Mad Money," (M-F, 6PM ET) featuring lively guest interviews, viewer calls and most important, the unmatched, fiery opinions of Cramer himself. He serves as the viewer's personal guide through the confusing jungle of Wall Street investing—navigating through both opportunities and pitfalls with one goal in mind—to help them make money.

Cramer is also co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street" (M-F, 9AM-11AM ET) and the founder of TheStreet, a multimedia provider of financial commentary.

He graduated from Harvard College where he was president and editor-in-chief of the prestigious daily, The Harvard Crimson. After graduation, he became a reporter for the Tallahassee Democrat and later for the Los Angeles Herald Examiner, where he covered stories ranging from homicides to sporting events.

Cramer is a former hedge fund manager and founder/owner and senior partner of Cramer Berkowitz. His compounded rate of return was 24 percent after all fees for 14 years at Cramer Berkowitz. He retired from his hedge fund in 2001, where he finished with one of the best records in the business, including having 36 percent-plus year in 2000.

He helped Steve Brill launch American Lawyer magazine before attending Harvard Law School and earning a law degree. Upon graduating and passing the New York State Bar Examination and being admitted to the N.Y. State Bar, Cramer joined Goldman Sachs in sales and trading. While at Goldman, Cramer wrote for The New Republic about stock market issues.

In December 2013, he published the book, "Jim Cramer's Get Rich Carefully," in which he creates a guide to high-yield, low-risk investing. Cramer is also the author of "Jim Cramer's Getting Back to Even," "Stay Mad for Life: Get Rich, Stay Rich," "Mad Money: Watch TV, Get Rich," "Jim Cramer's RealMoney" and "Confessions of a Street Addict."

Bertha Coombs

Bertha Coombs is a reporter for CNBC, covering financial markets, business news stories and health care throughout the business day. She is based at the Nasdaq Marketsite in Times Square.

Her health care coverage at CNBC has ranged from covering the implementation of the Affordable Care Act and the failed launch of the Obamacare health insurance exchanges, to how cancer researchers are using IBM's Watson to improve cancer care, and how doctors are using mobile technology to treat patients in their own homes. She also covered the devastation of Hurricane Katrina in New Orleans, the impact of the financial crisis of 2008, and reported on the oil markets from the floor of the New York Mercantile exchange.

Before joining CNBC, Coombs was a reporter and anchor for the pioneering online business network, Yahoo Finance Vision, and served as a freelance reporter for the former CNNfn financial network. Prior, she served as a reporter for ABC News One, and a substitute anchor for "World News Now" and "World News This Morning."

She began her career in general news, with previous reporting and anchoring positions at WABC-TV in New York, WPLG-TV in Miami and WFSB-TV in Hartford, Connecticut.

Coombs is a graduate of Yale University and was awarded the Leo Beranek Reporter Training Fellowship at WCVB-TV in Boston. Born in Havana, Cuba, she speaks fluent Spanish.

Tyler Mathisen

Tyler Mathisen co-anchors CNBC's "Power Lunch" (M-F, 1PM-3PM ET), one of the network's longest running program franchises. He is also Vice President, Events Strategy for CNBC, working closely with the network's events team to grow the rapidly expanding business.

Previously, Mathisen was co-anchor of "Nightly Business Report," an award-winning evening business news program produced by CNBC for U.S. public television. In 2014, NBR was named best radio/TV show by the Society of American Business Editors and Writers (SABEW). Since joining CNBC in 1997, Mathisen has held a number of positions including managing editor of CNBC Business News, responsible for directing the network's daily content and coverage. He was also co-anchor of CNBC's "Closing Bell."

Mathisen has reported one-hour documentaries for the network including "Best Buy: The Big Box Fights Back," "Supermarkets Inc: Inside a $500 Billion Money Machine" and "Death: It's a Living." Mathisen was also host of the CNBC series "How I Made My Millions."

Prior to CNBC, Mathisen spent 15 years as a writer, senior editor and top editor for Money magazine. Among other duties, he supervised the magazine's mutual funds coverage, its annual investment forecast issue and its expansion into electronic journalism, for which it won the first-ever National Magazine Award for New Media in 1997.

In 1993, Mathisen won the American University-Investment Company Institute Award for Personal Finance Journalism for a televised series on "Caring for Aging Parents," which aired on ABC's "Good Morning America." Mathisen served as money editor of "GMA" from 1991 to 1997. He also won an Emmy Award for a report on the 1987 stock market crash that aired on New York's WCBS-TV.

A native of Arlington,Va., Mathisen graduated with distinction from the University of Virginia.

Meg Tirrell

Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to and is based at the network's global headquarters in Englewood Cliffs, N.J.

Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.

Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.

She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.


GSK’s Race to Bring an RSV Vaccine to Market

The race to bring the world’s first respiratory syncytial virus (RSV) vaccine to market is underway, with GSK first out of the gate for FDA regulatory review this May. But competitors, including Pfizer, Sanofi and AstraZeneca, are also angling for a share of this estimated $10 billion dollar market. In a rare interview, CNBC’s Jim Cramer sits down with CEO Emma Walmsley to learn how the global biopharma giant plans to protect its desired RSV vax turf, replenish its drug portfolio, future R&D spend and the 2023 runway for growth. 

Emma Walmsley, GSK CEO
Interviewer: Jim Cramer, CNBC “Mad Money w/ Jim Cramer” Host, “Squawk on the Street” Co-Anchor 

Watch the full interview

Leading the Way in Today’s Global Biotech Market

Despite a prolonged slowdown in the global biotech market, investors continue to raise record levels of capital across existing and novel funds. Noted life science investor Stephen Squinto examines the state of deal flows, capital markets, safe havens and best opportunities for 2023 and the future.  

Stephen Squinto, J.P. Morgan Life Sciences Private Capital Chief Investment Officer & Managing Director
Interviewer: Dominic Chu, CNBC Senior Markets Correspondent

Watch the full interview

Cancer Breakthroughs at MD Anderson

The University of Texas MD Anderson Cancer Center is one of the world’s leading centers devoted exclusively to cancer research, prevention and care. A renowned cancer surgeon, researcher, professor and health system leader, Dr. Pisters shares some of the most innovative cell therapies MD Anderson is developing, including the evolving and expanding use of immunotherapy.  

Dr. Peter WT Pisters, The University of Texas MD Anderson Cancer Center President
Interviewer: Meg Tirrell, CNBC Senior Health & Science Reporter

Watch the full interview

Unlocking AI’s Potential in Medicine

Artificial intelligence continues to transform life sciences with breathtaking speed. With the application of computation in health care comes trailblazing scientific discoveries, earlier cancer detection, personalized oncology therapies, and better patient outcomes. An insightful conversation about the most promising investment opportunities and commercial applications at the intersection of AI, health care and precision medicine. 

Dr. Vineeta Agarwala, Andreessen Horowitz General Partner
Jim Breyer, Breyer Capital Founder & CEO
Dr. Sanjiv Patel, Relay Therapeutics President & CEO
Moderator: Meg Tirrell, CNBC Senior Health & Science Reporter

Watch the full interview

Amazon Clinic Delivers on Connected Care

Telehealth and digital wellness spending is estimated to reach more than $32 billion this year. Given the size and breadth of this market, Amazon Clinic enters a crowded field with the promise of saving customers time and money. The virtual health clinic offers prescription renewals and digital care for everything from asthma, high blood pressure, migraines and allergies. Amazon Clinic’s Chief Medical Officer Dr. Nworah Ayogu explains how Amazon is delivering digital health care in 2023 and beyond. 

Dr. Nworah Ayogu, Amazon Clinic Chief Medical Officer & GM
Interviewer: Bertha Coombs, CNBC Reporter 

Watch the full interview

The View from Washington

Dr. Shah, noted health policy expert and global private equity investor, joins us for a wide-ranging conversation on what’s to come from the FDA in 2023, drug pricing and the potential for a Medicare bailout. Plus, his take on the biotech investment landscape and the impact of SVB bank crisis on investors and startups.  

Dr. Anand Shah, Clayton, Dubilier & Rice Operating Advisor, Former FDA Deputy Commissioner & Chief Medical Officer, Centers for Medicare & Medicaid Innovation
Interviewer: Tyler Mathisen, CNBC “Power Lunch” Co-Anchor & Vice President, Events Strategy

Watch the full interview

Why Novo Nordisk’s Drugs Are Anti-Obesity Game-Changers

Weight-loss drugs like Ozempic and Wegovy are getting all the buzz lately — discussed on social media, whispered about at dinner parties and endorsed by celebs and tech billionaires. All good news for Danish biopharma Novo Nordisk, which manufactures both medications and has seen sales skyrocket in response to strong global demand. Novo Nordisk’s CEO and the company’s Head of Global Drug Discovery discuss the science, safety, innovation and future growth behind these blockbuster drugs and the coming showdown with expected new entry, Eli Lilly. 

Lars Fruergaard Jørgensen, Novo Nordisk A/S President & CEO 
Karin Conde-Knape, Novo Nordisk Senior Vice President for Global Drug Discovery
Moderator: Meg Tirrell, CNBC Senior Health & Science Reporter 

Watch the full interview